Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat

E. Pozzi, M. Salmona, P. Masturzo, M. Genghini, M. Scelsi, L. Spialtini, Maurizio Luisetti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The events leading to the onset of the experimental bleomycin-induced pulmonary fibrosis are so far unknown, though recent observations emphasize the crucial role played by lung phospholipids and by alveolar macrophages. In an attempt to verify this point, a series of studies were undertaken by treating rats (CD-COBS) with intratracheal instillation of a single dose of bleomycin (1.5 U). At the same time a group of animals was pretreated with ambroxol (which is known to be a powerful inducer of surfactant production both in fetal and adult type II pneumocytes), 4 mg/kg body weight/day per os, 5 days before the treatment with bleomycin and up to the sacrifice of the animals at the 1st, 3rd, 7th, 14th or 28th day from the instillation. In our experimental model, the 14th day from the treatment with bleomycin seems to be a crucial time since it histologically corresponds to the proliferation of type II pneumocytes; furthermore, an increase of total lecithins in the alveolar spaces was observed, together with an increase of macrophage membrane fluidity. In the ambroxol-pre-treated group a partial reduction of the rate of interstitial fibrosis was observed. At the 14th day from treatment the alteration of phospholipid levels was much less pronounced and the microviscosity of alveolar macrophages was similar to that of control animals. These data suggest that the onset of bleomycin-induced pulmonary fibrosis in the rat is characterized by an increase of alveolar lecithins and that this fact could modify the physico-chemical peculiarities of alveolar macrophages. Ambroxol shows a partially protective effect, perhaps by modulating the activity of type II pneumocytes.

Original languageEnglish
Pages (from-to)23-32
Number of pages10
JournalRespiration
Volume51
DOIs
Publication statusPublished - 1987

Fingerprint

Pulmonary Fibrosis
Bleomycin
Ambroxol
Phospholipids
Alveolar Epithelial Cells
Alveolar Macrophages
Lecithins
Membrane Fluidity
Surface-Active Agents
Fibrosis
Theoretical Models
Macrophages
Body Weight
indium-bleomycin
Lung

Keywords

  • Ambroxol
  • Bleomycin
  • Fibrosis in rat
  • Lung
  • Phospholipids content

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology

Cite this

Pozzi, E., Salmona, M., Masturzo, P., Genghini, M., Scelsi, M., Spialtini, L., & Luisetti, M. (1987). Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat. Respiration, 51, 23-32. https://doi.org/10.1159/000195271

Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat. / Pozzi, E.; Salmona, M.; Masturzo, P.; Genghini, M.; Scelsi, M.; Spialtini, L.; Luisetti, Maurizio.

In: Respiration, Vol. 51, 1987, p. 23-32.

Research output: Contribution to journalArticle

Pozzi, E, Salmona, M, Masturzo, P, Genghini, M, Scelsi, M, Spialtini, L & Luisetti, M 1987, 'Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat', Respiration, vol. 51, pp. 23-32. https://doi.org/10.1159/000195271
Pozzi, E. ; Salmona, M. ; Masturzo, P. ; Genghini, M. ; Scelsi, M. ; Spialtini, L. ; Luisetti, Maurizio. / Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat. In: Respiration. 1987 ; Vol. 51. pp. 23-32.
@article{74f56aa762fc4942a0c09799fdfcf3d1,
title = "Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat",
abstract = "The events leading to the onset of the experimental bleomycin-induced pulmonary fibrosis are so far unknown, though recent observations emphasize the crucial role played by lung phospholipids and by alveolar macrophages. In an attempt to verify this point, a series of studies were undertaken by treating rats (CD-COBS) with intratracheal instillation of a single dose of bleomycin (1.5 U). At the same time a group of animals was pretreated with ambroxol (which is known to be a powerful inducer of surfactant production both in fetal and adult type II pneumocytes), 4 mg/kg body weight/day per os, 5 days before the treatment with bleomycin and up to the sacrifice of the animals at the 1st, 3rd, 7th, 14th or 28th day from the instillation. In our experimental model, the 14th day from the treatment with bleomycin seems to be a crucial time since it histologically corresponds to the proliferation of type II pneumocytes; furthermore, an increase of total lecithins in the alveolar spaces was observed, together with an increase of macrophage membrane fluidity. In the ambroxol-pre-treated group a partial reduction of the rate of interstitial fibrosis was observed. At the 14th day from treatment the alteration of phospholipid levels was much less pronounced and the microviscosity of alveolar macrophages was similar to that of control animals. These data suggest that the onset of bleomycin-induced pulmonary fibrosis in the rat is characterized by an increase of alveolar lecithins and that this fact could modify the physico-chemical peculiarities of alveolar macrophages. Ambroxol shows a partially protective effect, perhaps by modulating the activity of type II pneumocytes.",
keywords = "Ambroxol, Bleomycin, Fibrosis in rat, Lung, Phospholipids content",
author = "E. Pozzi and M. Salmona and P. Masturzo and M. Genghini and M. Scelsi and L. Spialtini and Maurizio Luisetti",
year = "1987",
doi = "10.1159/000195271",
language = "English",
volume = "51",
pages = "23--32",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat

AU - Pozzi, E.

AU - Salmona, M.

AU - Masturzo, P.

AU - Genghini, M.

AU - Scelsi, M.

AU - Spialtini, L.

AU - Luisetti, Maurizio

PY - 1987

Y1 - 1987

N2 - The events leading to the onset of the experimental bleomycin-induced pulmonary fibrosis are so far unknown, though recent observations emphasize the crucial role played by lung phospholipids and by alveolar macrophages. In an attempt to verify this point, a series of studies were undertaken by treating rats (CD-COBS) with intratracheal instillation of a single dose of bleomycin (1.5 U). At the same time a group of animals was pretreated with ambroxol (which is known to be a powerful inducer of surfactant production both in fetal and adult type II pneumocytes), 4 mg/kg body weight/day per os, 5 days before the treatment with bleomycin and up to the sacrifice of the animals at the 1st, 3rd, 7th, 14th or 28th day from the instillation. In our experimental model, the 14th day from the treatment with bleomycin seems to be a crucial time since it histologically corresponds to the proliferation of type II pneumocytes; furthermore, an increase of total lecithins in the alveolar spaces was observed, together with an increase of macrophage membrane fluidity. In the ambroxol-pre-treated group a partial reduction of the rate of interstitial fibrosis was observed. At the 14th day from treatment the alteration of phospholipid levels was much less pronounced and the microviscosity of alveolar macrophages was similar to that of control animals. These data suggest that the onset of bleomycin-induced pulmonary fibrosis in the rat is characterized by an increase of alveolar lecithins and that this fact could modify the physico-chemical peculiarities of alveolar macrophages. Ambroxol shows a partially protective effect, perhaps by modulating the activity of type II pneumocytes.

AB - The events leading to the onset of the experimental bleomycin-induced pulmonary fibrosis are so far unknown, though recent observations emphasize the crucial role played by lung phospholipids and by alveolar macrophages. In an attempt to verify this point, a series of studies were undertaken by treating rats (CD-COBS) with intratracheal instillation of a single dose of bleomycin (1.5 U). At the same time a group of animals was pretreated with ambroxol (which is known to be a powerful inducer of surfactant production both in fetal and adult type II pneumocytes), 4 mg/kg body weight/day per os, 5 days before the treatment with bleomycin and up to the sacrifice of the animals at the 1st, 3rd, 7th, 14th or 28th day from the instillation. In our experimental model, the 14th day from the treatment with bleomycin seems to be a crucial time since it histologically corresponds to the proliferation of type II pneumocytes; furthermore, an increase of total lecithins in the alveolar spaces was observed, together with an increase of macrophage membrane fluidity. In the ambroxol-pre-treated group a partial reduction of the rate of interstitial fibrosis was observed. At the 14th day from treatment the alteration of phospholipid levels was much less pronounced and the microviscosity of alveolar macrophages was similar to that of control animals. These data suggest that the onset of bleomycin-induced pulmonary fibrosis in the rat is characterized by an increase of alveolar lecithins and that this fact could modify the physico-chemical peculiarities of alveolar macrophages. Ambroxol shows a partially protective effect, perhaps by modulating the activity of type II pneumocytes.

KW - Ambroxol

KW - Bleomycin

KW - Fibrosis in rat

KW - Lung

KW - Phospholipids content

UR - http://www.scopus.com/inward/record.url?scp=0023272394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023272394&partnerID=8YFLogxK

U2 - 10.1159/000195271

DO - 10.1159/000195271

M3 - Article

C2 - 2440083

AN - SCOPUS:0023272394

VL - 51

SP - 23

EP - 32

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

ER -